Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Hay

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
British Journal of Pharmacology|April 20, 2001
Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout miceD W Hay, S A Douglas, Z Ao, et al.
Annals of the New York Academy of Sciences|January 1, 1991
The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonistT J Torphy, I Faiferman, J G Gleason, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonistE H Ohlstein, P Nambi, A Lago, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1989
The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienesT J Torphy, J F Newton, M A Wasserman, et al.
Molecular Pharmacology|August 23, 2000
Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human originH M Sarau, J L Mooney, D B Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1987
Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airwaysD W Hay, R M Muccitelli, S S Tucker, et al.
Journal of Medicinal Chemistry|June 6, 1997
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide frameworkG A Giardina, H M Sarau, C Farina, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in miceD E Griswold, S A Douglas, L D Martin, et al.
Molecular Pharmacology|September 25, 1999
Endothelin B receptor modulates inflammatory pain and cutaneous inflammationD E Griswold, S A Douglas, L D Martin, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
British Journal of Pharmacology|April 20, 2001
Differential modulation of endothelin ligand-induced contraction in isolated tracheae from endothelin B (ET(B)) receptor knockout miceD W Hay, S A Douglas, Z Ao, et al.
Annals of the New York Academy of Sciences|January 1, 1991
The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonistT J Torphy, I Faiferman, J G Gleason, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonistE H Ohlstein, P Nambi, A Lago, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pigD C Underwood, S Bochnowicz, R R Osborn, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1989
The bronchopulmonary pharmacology of SK&F 104353 in anesthetized guinea pigs: demonstration of potent and selective antagonism of responses to peptidoleukotrienesT J Torphy, J F Newton, M A Wasserman, et al.
Molecular Pharmacology|August 23, 2000
Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human originH M Sarau, J L Mooney, D B Schmidt, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1987
Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airwaysD W Hay, R M Muccitelli, S S Tucker, et al.
Journal of Medicinal Chemistry|June 6, 1997
Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide frameworkG A Giardina, H M Sarau, C Farina, et al.
Journal of Cardiovascular Pharmacology|November 15, 2000
Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in miceD E Griswold, S A Douglas, L D Martin, et al.
Molecular Pharmacology|September 25, 1999
Endothelin B receptor modulates inflammatory pain and cutaneous inflammationD E Griswold, S A Douglas, L D Martin, et al.
Pageof 12